Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.
Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. Kratzer R, et al. Among authors: silvestre n. Hum Vaccin Immunother. 2018 Jun 3;14(6):1417-1422. doi: 10.1080/21645515.2018.1433970. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29388874 Free PMC article.
An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.
Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul JM, Barry R, Inchauspé G. Fournillier A, et al. Among authors: silvestre n. Vaccine. 2007 Oct 16;25(42):7339-53. doi: 10.1016/j.vaccine.2007.08.020. Epub 2007 Aug 31. Vaccine. 2007. PMID: 17875349
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G. Martin P, et al. Among authors: silvestre n. Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041. Epub 2014 Nov 26. Gut. 2015. PMID: 25429051 Free PMC article.
A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates.
Leung-Theung-Long S, Gouanvic M, Coupet CA, Ray A, Tupin E, Silvestre N, Marchand JB, Schmitt D, Hoffmann C, Klein M, Seegren P, Huaman MC, Cristillo AD, Inchauspé G. Leung-Theung-Long S, et al. Among authors: silvestre n. PLoS One. 2015 Nov 24;10(11):e0143552. doi: 10.1371/journal.pone.0143552. eCollection 2015. PLoS One. 2015. PMID: 26599077 Free PMC article.
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.
Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, Brandely R, Villeval D, Rittner K, Silvestre N, Erbs P, Zitvogel L, Quéméneur E, Préville X, Marchand JB. Kleinpeter P, et al. Among authors: silvestre n. Oncoimmunology. 2016 Sep 9;5(10):e1220467. doi: 10.1080/2162402X.2016.1220467. eCollection 2016. Oncoimmunology. 2016. PMID: 27853644 Free PMC article.
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.
Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, Hoffmann C, Schultz H, Tyagi S, Soni H, Converse PJ, Arias L, Kleinpeter P, Sansas B, Mdluli K, Vilaplana C, Cardona PJ, Nuermberger E, Marchand JB, Silvestre N, Inchauspé G. Leung-Theung-Long S, et al. Among authors: silvestre n. PLoS One. 2018 May 2;13(5):e0196815. doi: 10.1371/journal.pone.0196815. eCollection 2018. PLoS One. 2018. PMID: 29718990 Free PMC article.
By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Kleinpeter P, Remy-Ziller C, Winter E, Gantzer M, Nourtier V, Kempf J, Hortelano J, Schmitt D, Schultz H, Geist M, Brua C, Hoffmann C, Schlesinger Y, Villeval D, Thioudellet C, Erbs P, Foloppe J, Silvestre N, Fend L, Quemeneur E, Marchand JB. Kleinpeter P, et al. Among authors: silvestre n. J Virol. 2019 May 15;93(11):e00207-19. doi: 10.1128/JVI.00207-19. Print 2019 Jun 1. J Virol. 2019. PMID: 30918073 Free PMC article.
Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques.
Vierboom MPM, Chenine AL, Darrah PA, Vervenne RAW, Boot C, Hofman SO, Sombroek CC, Dijkman K, Khayum MA, Stammes MA, Haanstra KG, Hoffmann C, Schmitt D, Silvestre N, White AG, Borish HJ, Seder RA, Ouaked N, Leung-Theung-Long S, Inchauspé G, Anantha R, Limbach M, Evans TG, Casimiro D, Lempicki M, Laddy DJ, Bonavia A, Verreck FAW. Vierboom MPM, et al. Among authors: silvestre n. NPJ Vaccines. 2020 May 14;5(1):39. doi: 10.1038/s41541-020-0189-2. eCollection 2020. NPJ Vaccines. 2020. PMID: 32435513 Free PMC article.
51 results